S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Wall Street adds more to its big January after strong week
Italy's premier visits Libya for talks on energy, migration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Wall Street adds more to its big January after strong week
Italy's premier visits Libya for talks on energy, migration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Wall Street adds more to its big January after strong week
Italy's premier visits Libya for talks on energy, migration
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Visa, L3Harris rise; Intel, Eastman Chemical fall
The Next Big Crisis Is Here (Ad)
How major US stock indexes fared Friday 1/27/2023
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Wall Street adds more to its big January after strong week
Italy's premier visits Libya for talks on energy, migration
NASDAQ:BIOC

Biocept - BIOC Stock Forecast, Price & News

$0.55
0.00 (0.00%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.54
$0.58
50-Day Range
$0.47
$0.84
52-Week Range
$0.46
$2.99
Volume
41,224 shs
Average Volume
275,454 shs
Market Capitalization
$9.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Biocept MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
624.0% Upside
$4.00 Price Target
Short Interest
Healthy
0.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.10mentions of Biocept in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars


BIOC stock logo

About Biocept (NASDAQ:BIOC) Stock

Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.

Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Stock News Headlines

Biocept, Inc. (NASDAQ:BIOC) Short Interest Update
Biocept (NASDAQ:BIOC) Now Covered by Analysts at StockNews.com
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Biocept Reports Third Quarter 2022 Financial Results
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Biocept Reports Second Quarter 2022 Financial Results
Form 8-K BIOCEPT INC For: Oct 18 - StreetInsider.com
Biocept to Present at the LD Micro Main Event XV
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

BIOC Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
4/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOC
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+624.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-2,820,000.00
Pretax Margin
-32.74%

Debt

Sales & Book Value

Annual Sales
$61.25 million
Book Value
$2.23 per share

Miscellaneous

Free Float
16,822,000
Market Cap
$9.43 million
Optionable
Optionable
Beta
0.82

Key Executives

  • Samuel D. Riccitelli
    Chairman, President & Chief Executive Officer
  • Philippe Marchand
    Chief Operating Officer
  • Antonino Morales
    Chief Financial Officer, Secretary & Director
  • Michael C. Dugan
    Chief Medical Officer & Medical Director
  • Darrell Taylor
    SVP, Chief Legal & Compliance Officer













BIOC Stock - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

What is Biocept's stock price forecast for 2023?

1 analysts have issued twelve-month price objectives for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next year. This suggests a possible upside of 624.0% from the stock's current price.
View analysts price targets for BIOC
or view top-rated stocks among Wall Street analysts.

How have BIOC shares performed in 2023?

Biocept's stock was trading at $0.53 on January 1st, 2023. Since then, BIOC stock has increased by 4.2% and is now trading at $0.5525.
View the best growth stocks for 2023 here
.

Are investors shorting Biocept?

Biocept saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 143,500 shares, an increase of 93.7% from the December 31st total of 74,100 shares. Based on an average daily volume of 131,600 shares, the days-to-cover ratio is presently 1.1 days.
View Biocept's Short Interest
.

When is Biocept's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 5th 2023.
View our BIOC earnings forecast
.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings data on Thursday, November, 10th. The medical research company reported ($0.31) EPS for the quarter. The medical research company earned $10.61 million during the quarter. Biocept had a negative net margin of 32.99% and a negative trailing twelve-month return on equity of 49.18%.

When did Biocept's stock split?

Biocept's stock reverse split on the morning of Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

How do I buy shares of Biocept?

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $0.55.

How much money does Biocept make?

Biocept (NASDAQ:BIOC) has a market capitalization of $9.43 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How many employees does Biocept have?

The company employs 104 workers across the globe.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.

This page (NASDAQ:BIOC) was last updated on 1/28/2023 by MarketBeat.com Staff